NCT05489926View on ClinicalTrials.gov

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG

Pamiparib

Pamiparib, 60mg PO BID

Trial Locations (1)

Unknown

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER